Non-randomized, open-label, multicenter phase II Study for the treatment of
- 25 R/R BPDCN-IF (CD123/CD4/CD56 positive) AML patients and
- 25 patients presenting R/R AML CD123+, but negative for either, or both, CD4 and CD56.
Patients will be treated with 12 mcg/kg/day of tagraxofusp for 5 days, for at least 4 cicles.
- The patient has evidence of AML in the peripheral blood and/or bone marrow with either
BPDCN-IF [CD123/CD4/CD56 (+)] or with AML that is CD123+ but negative for either, or
both, CD4 and CD56.
- The patient is ≥18 years old.
- The patient must be refractory to at least one previous line of conventional therapy
(either high dose therapy or hypomethylating agents) or relapsed after receiving
conventional therapy (a maximum of two previous line of therapy is admitted).
- The patient has an Eastern Cooperative Oncology Group (ECOG) performance score (PS) of
0 to 2.
- The patient has adequate baseline organ function, including cardiac, renal, and
1. Left ventricular ejection fraction (LVEF) ≥institutional lower limit of normal as
measured by multigated acquisition (MUGA) scan or 2-dimensional (2-D)
echocardiography(ECHO) within 21 days before start of therapy and no clinically
significant abnormalities on a 12-lead electrocardiogram (ECG).
2. Serum creatinine ≤1.5 mg/dL (133 μmol/L).
3. Serum albumin ≥3.2 g/dL (32 g/L) (albumin infusions are not permitted to enable
4. Bilirubin ≤1.5 mg/dL (26 μmol/L).
5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 times
the upper limit of normal (ULN).
- If the patient is a woman of childbearing potential (WOCBP), she must have a negative
serum or urine pregnancy test at screeningwithin 1 week before treatment.
- The patient has signed informed consent before initiation of any study-specific
procedures or treatment.
- The patient is able to adhere to the study visit schedule and other protocol
requirements, including follow-up for survival assessment.
- The patient (male and female) agrees to use acceptable contraceptive methods for the
duration of time on the study and continue to use acceptable contraceptive methods for
1 week after the last infusion of tagraxofusp.
- The patient has a diagnosis of acute promyelocytic leukemia (APL; FAB subtype M3).
- The patient has persistent clinically significant toxicities of Grade≥2 from previous
chemotherapy (excluding alopecia, nausea, fatigue, and liver function tests [as
mandated in the inclusion criteria]).
- The patient has received treatment with chemotherapy, wide-field radiation, or
biologic therapy within 14 days of study entry.
- The patient has received treatment with an investigational agent within 14 days of
- The patient has previously received treatment with tagraxofusp.
- The patient has an active malignancy and/or cancer history (excluding antecedent MDS)
that may confound the assessment of the study endpoints. Patients with a past cancer
history (within 2 years of entry) with substantial potential for recurrence and/or
ongoing active malignancy will be evaluated on a case by case basis. Patients with the
following neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in
situ, cervical intraepithelial neoplasia, organ-confined prostate cancer with no
evidence of progressive disease.
- The patient has clinically significant cardiovascular disease (eg, uncontrolled or any
New York Heart Association Class 3 or 4 congestive heart failure, uncontrolled angina,
history of myocardial infarction, unstable angina or stroke within 6 months before
study entry, uncontrolled hypertension or clinically significant arrhythmias not
controlled by medication).
- The patient has uncontrolled, clinically significant pulmonary disease (eg, chronic
obstructive pulmonary disease, pulmonary hypertension) that, in the opinion of the
Investigator, would put the patient at significant risk for pulmonary complications
during the study.
- The patient has known active or suspected central nervous system (CNS) leukemia. If
suspected, CNS leukemia should be ruled out with relevant imaging and/or examination
of cerebrospinal fluid.
- The patient is receiving immunosuppressive therapy - with the exception of low-dose
prednisone (≤10 mg/day) - for treatment or prophylaxis of graft-versus-host disease
(GVHD). If the patient has been on immunosuppressive treatment or prophylaxis for
GVHD, the treatment(s) must have been discontinued at least 14 days before study
treatment and there must be no evidence of Grade ≥2 GVHD.
- The patient has uncontrolled intercurrent illness including, but not limited to,
uncontrolled infection, disseminated intravascular coagulation, or psychiatric
illness/social situations that would limit compliance with study requirements.
- The patient is pregnant or breastfeeding.
- The patient has known positive status for human immunodeficiency virus or active or
chronic hepatitis B or hepatitis C (Patients with positive serology for HBV can be
enrolled and must receive antiviral prophylaxis - i.e lamivudine or entcavir).
- The patient is oxygen-dependent.
- The patient has any medical condition that, in the opinion of the Investigator, places
the patient at an unacceptably high risk for toxicities.
- The patient has AML and requires more than 1 g/day of hydroxyurea
(Hydroxyureaispermittedatdoses of ≤1 g/day.)